<p>Ashton Thomas Private Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第三季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股减少了 79.7%。该机构投资者在该季度出售了 7,913 股后，持有 2,012 股该生物技术公司的股票。截至其最近的 SEC 文件，Ashton Thomas Private Wealth LLC 在联合治疗公司的持股价值为 843,000 美元。</p>
<ul>
<li>全球顶级对冲基金的三大股票推荐</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也增加或减少了在该公司的股份。Geneos Wealth Management Inc. 在第一季度将其在联合治疗公司的股份增加了 141.7%。Geneos Wealth Management Inc. 目前持有 145 股该生物技术公司的股票，价值 45,000 美元，在此期间又购买了 85 股。Vontobel Holding Ltd. 在第二季度将其在联合治疗公司的股份增加了 12.0%。Vontobel Holding Ltd. 目前持有 1,487 股该生物技术公司的股票，价值 427,000 美元，在上个季度又购买了 159 股。US Bancorp DE 在第二季度将其在联合治疗公司的股份增加了 16.6%。US Bancorp DE 目前持有 2,299 股该生物技术公司的股票，价值 661,000 美元，在上个季度又购买了 328 股。Blair William &amp; Co. IL 在第二季度将其在联合治疗公司的持股增加了 22.1%。Blair William &amp; Co. IL 目前持有 1,343 股该生物技术公司的股票，价值 386,000 美元，在此期间又购买了 243 股。最后，Callan Family Office LLC 在第二季度将其在联合治疗公司的股份增加了 258.3%。Callan Family Office LLC 目前持有 3,468 股该生物技术公司的股票，价值 997,000 美元，在上个季度又购买了 2,500 股。对冲基金和其他机构投资者持有该公司 94.08% 的股票。</p>
<p>获取 <strong>联合治疗</strong> 的提醒：</p>
<h2>联合治疗的内部活动</h2>
<p>在其他新闻中，执行副总裁 Paul A. Mahon 在 2 月 5 日（星期四）出售了 8,300 股该股票。股票的平均售价为 483.25 美元，总价值为 4,010,975.00 美元。出售完成后，该执行副总裁直接持有 36,781 股公司的股票，估值约为 17,774,418.25 美元。这代表其持股减少了 18.41%。该交易已在向证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席运营官 Michael Benkowitz 在 2 月 2 日（星期一）出售了 22,500 股公司的股票。股票的平均售价为 470.95 美元，总交易额为 10,596,375.00 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 542,214 股公司股票，价值 260,031,533 美元。当前公司内部人士持有 10.30% 的股票。</p>
<h2>联合治疗的价格表现</h2>
<ul>
<li>Liquidia：法院胜利唤醒行业巨头？</li>
</ul>
<p>NASDAQ:UTHR 的股票在周五开盘价为 485.36 美元。联合治疗公司的 12 个月低点为 266.98 美元，12 个月高点为 519.99 美元。该公司的市值为 209 亿美元，市盈率为 18.39，市盈率/增长比率为 2.58，贝塔值为 0.85。公司的 50 日移动平均价格为 486.75 美元，200 日移动平均价格为 427.47 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 UTHR 股票发表了评论。瑞银集团在 1 月 6 日的研究报告中将联合治疗的目标价格从 600.00 美元上调至 645.00 美元，并给予该股票 “买入” 评级。杰富瑞金融集团在 11 月 19 日的研究报告中重申了 “买入” 评级，并对联合治疗的股票设定了 575.00 美元的目标价。摩根士丹利在 10 月 29 日的研究报告中对联合治疗的股票设定了 447.00 美元的目标价格。HC Wainwright 在 10 月 30 日的研究报告中将联合治疗的股票目标价格从 500.00 美元上调至 525.00 美元，并给予该股票 “买入” 评级。最后，加拿大皇家银行在 10 月 30 日的研究报告中将联合治疗的股票目标价格从 569.00 美元上调至 587.00 美元，并给予该股票 “跑赢大盘” 评级。八位研究分析师对该股票给予了 “买入” 评级，三位分析师对公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，联合治疗的平均评级为 “适度买入”，共识目标价格为 509.50 美元。</p>
<ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
<p><strong>查看我们关于联合治疗的最新研究报告</strong></p>
<h2>联合治疗公司简介</h2>
<p>（免费报告）</p>
<p>联合治疗公司 NASDAQ: UTHR 是一家生物技术公司，致力于开发和商业化独特产品，以应对危及生命的疾病。该公司的主要关注点是肺动脉高压（PAH），已推出几种旨在改善患者功能能力和生活质量的疗法。其市场产品包括持续输注特瑞普利（Remodulin）、吸入特瑞普利（Tyvaso）、口服特瑞普利（Orenitram）和他达拉非（Adcirca），每种产品都针对不同的给药方式和患者需求。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过联合治疗</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>没有人在谈论的购买狂潮</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
</ul>
<p><strong>想知道其他对 UTHR 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取 United Therapeutics Corporation (NASDAQ:UTHR - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 United Therapeutics 吗？</h2>
<p>在你考虑投资 United Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 United Therapeutics 并不在名单上。</p>
<p>虽然 United Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

联合治疗

<p>Ashton Thomas Private Wealth LLC 在第三季度减少了对联合治疗公司的持股，减幅达到 79.7%，目前持有 2,012 股，价值 843,000 美元。其他机构投资者也调整了他们的持股，Geneos Wealth Management 增加了 141.7% 的持仓。内部人士在过去三个月内共售出 542,214 股，价值 2.6 亿美元。该股票开盘价为 485.36 美元，12 个月的价格区间为 266.98 美元至 519.99 美元。分析师设定的目标价在 447.00 美元至 645.00 美元之间，大多数分析师给予其 “买入” 评级</p>

<p>Ashton Thomas Private Wealth LLC cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 79.7% during the third quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 2,012 shares of the biotechnology company's stock after selling 7,913 shares during the quarter. Ashton Thomas Private Wealth LLC's holdings in United Therapeutics were worth $843,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Ashton Thomas Private Wealth LLC 在最近向证券交易委员会提交的文件中表示，在第三季度将其在联合治疗公司（NASDAQ:UTHR - 免费报告）的持股减少了 79.7%。该机构投资者在该季度出售了 7,913 股后，持有 2,012 股该生物技术公司的股票。截至其最近的 SEC 文件，Ashton Thomas Private Wealth LLC 在联合治疗公司的持股价值为 843,000 美元。</p>
</div><ul>
<li>The Top 3 Stock Picks at the World’s Greatest Hedge Fund</li>
</ul>
<div class="lb-trans"><ul>
<li>全球顶级对冲基金的三大股票推荐</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares during the period. Vontobel Holding Ltd. grew its stake in United Therapeutics by 12.0% during the 2nd quarter. Vontobel Holding Ltd. now owns 1,487 shares of the biotechnology company's stock worth $427,000 after purchasing an additional 159 shares in the last quarter. US Bancorp DE grew its stake in United Therapeutics by 16.6% during the 2nd quarter. US Bancorp DE now owns 2,299 shares of the biotechnology company's stock worth $661,000 after purchasing an additional 328 shares in the last quarter. Blair William &amp; Co. IL increased its holdings in United Therapeutics by 22.1% during the 2nd quarter. Blair William &amp; Co. IL now owns 1,343 shares of the biotechnology company's stock worth $386,000 after purchasing an additional 243 shares during the period. Finally, Callan Family Office LLC raised its position in United Therapeutics by 258.3% in the 2nd quarter. Callan Family Office LLC now owns 3,468 shares of the biotechnology company's stock valued at $997,000 after purchasing an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也增加或减少了在该公司的股份。Geneos Wealth Management Inc. 在第一季度将其在联合治疗公司的股份增加了 141.7%。Geneos Wealth Management Inc. 目前持有 145 股该生物技术公司的股票，价值 45,000 美元，在此期间又购买了 85 股。Vontobel Holding Ltd. 在第二季度将其在联合治疗公司的股份增加了 12.0%。Vontobel Holding Ltd. 目前持有 1,487 股该生物技术公司的股票，价值 427,000 美元，在上个季度又购买了 159 股。US Bancorp DE 在第二季度将其在联合治疗公司的股份增加了 16.6%。US Bancorp DE 目前持有 2,299 股该生物技术公司的股票，价值 661,000 美元，在上个季度又购买了 328 股。Blair William &amp; Co. IL 在第二季度将其在联合治疗公司的持股增加了 22.1%。Blair William &amp; Co. IL 目前持有 1,343 股该生物技术公司的股票，价值 386,000 美元，在此期间又购买了 243 股。最后，Callan Family Office LLC 在第二季度将其在联合治疗公司的股份增加了 258.3%。Callan Family Office LLC 目前持有 3,468 股该生物技术公司的股票，价值 997,000 美元，在上个季度又购买了 2,500 股。对冲基金和其他机构投资者持有该公司 94.08% 的股票。</p>
</div><p>Get <strong>United Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>联合治疗</strong> 的提醒：</p>
</div><h2>Insider Activity at United Therapeutics</h2>
<div class="lb-trans"><h2>联合治疗的内部活动</h2>
</div><p>In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $17,774,418.25. This represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $470.95, for a total transaction of $10,596,375.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 542,214 shares of company stock valued at $260,031,533 in the last three months. 10.30% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Paul A. Mahon 在 2 月 5 日（星期四）出售了 8,300 股该股票。股票的平均售价为 483.25 美元，总价值为 4,010,975.00 美元。出售完成后，该执行副总裁直接持有 36,781 股公司的股票，估值约为 17,774,418.25 美元。这代表其持股减少了 18.41%。该交易已在向证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席运营官 Michael Benkowitz 在 2 月 2 日（星期一）出售了 22,500 股公司的股票。股票的平均售价为 470.95 美元，总交易额为 10,596,375.00 美元。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去三个月中，内部人士共出售了 542,214 股公司股票，价值 260,031,533 美元。当前公司内部人士持有 10.30% 的股票。</p>
</div><h2>United Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>联合治疗的价格表现</h2>
</div><ul>
<li>Liquidia: Court victory the awakening of an industry giant?</li>
</ul>
<div class="lb-trans"><ul>
<li>Liquidia：法院胜利唤醒行业巨头？</li>
</ul>
</div><p>Shares of NASDAQ:UTHR opened at $485.36 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The firm has a market capitalization of $20.90 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.58 and a beta of 0.85. The company's fifty day moving average price is $486.75 and its 200 day moving average price is $427.47.</p>
<div class="lb-trans"><p>NASDAQ:UTHR 的股票在周五开盘价为 485.36 美元。联合治疗公司的 12 个月低点为 266.98 美元，12 个月高点为 519.99 美元。该公司的市值为 209 亿美元，市盈率为 18.39，市盈率/增长比率为 2.58，贝塔值为 0.85。公司的 50 日移动平均价格为 486.75 美元，200 日移动平均价格为 427.47 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently commented on UTHR shares. UBS Group boosted their price objective on United Therapeutics from $600.00 to $645.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, January 6th. Jefferies Financial Group reiterated a &#34;buy&#34; rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright lifted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, United Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $509.50.</p>
<div class="lb-trans"><p>一些股票分析师最近对 UTHR 股票发表了评论。瑞银集团在 1 月 6 日的研究报告中将联合治疗的目标价格从 600.00 美元上调至 645.00 美元，并给予该股票 “买入” 评级。杰富瑞金融集团在 11 月 19 日的研究报告中重申了 “买入” 评级，并对联合治疗的股票设定了 575.00 美元的目标价。摩根士丹利在 10 月 29 日的研究报告中对联合治疗的股票设定了 447.00 美元的目标价格。HC Wainwright 在 10 月 30 日的研究报告中将联合治疗的股票目标价格从 500.00 美元上调至 525.00 美元，并给予该股票 “买入” 评级。最后，加拿大皇家银行在 10 月 30 日的研究报告中将联合治疗的股票目标价格从 569.00 美元上调至 587.00 美元，并给予该股票 “跑赢大盘” 评级。八位研究分析师对该股票给予了 “买入” 评级，三位分析师对公司的股票给予了 “持有” 评级。根据 MarketBeat.com 的数据，联合治疗的平均评级为 “适度买入”，共识目标价格为 509.50 美元。</p>
</div><ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
</div><p><strong>View Our Latest Research Report on United Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于联合治疗的最新研究报告</strong></p>
</div><h2>United Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>联合治疗公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.</p>
<div class="lb-trans"><p>联合治疗公司 NASDAQ: UTHR 是一家生物技术公司，致力于开发和商业化独特产品，以应对危及生命的疾病。该公司的主要关注点是肺动脉高压（PAH），已推出几种旨在改善患者功能能力和生活质量的疗法。其市场产品包括持续输注特瑞普利（Remodulin）、吸入特瑞普利（Tyvaso）、口服特瑞普利（Orenitram）和他达拉非（Adcirca），每种产品都针对不同的给药方式和患者需求。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than United Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>The buying spree that no one is talking about</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过联合治疗</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>没有人在谈论的购买狂潮</li>
<li>特朗普的人工智能秘密：比英伟达快 100 倍</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding UTHR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 UTHR 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com 获取 United Therapeutics Corporation (NASDAQ:UTHR - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VVRIUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=UTHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in United Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 United Therapeutics 吗？</h2>
</div><p>Before you consider United Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 United Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 United Therapeutics 并不在名单上。</p>
</div><p>While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 United Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ashton Thomas Private Wealth LLC 出售了 United Therapeutics Corporation 的股票，股票代码为$UTHR